NCT05668897View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG171 Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

December 2, 2022

Study Completion Date

December 8, 2022

Conditions
COVID-19
Interventions
DRUG

GST-HG171

This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.

DRUG

placebo of GST-HG171

This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.

Trial Locations (1)

130021

The first hospital of Jilin University, Changchun

All Listed Sponsors
lead

Fujian Akeylink Biotechnology Co., Ltd.

INDUSTRY